Clinical Data Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test BioPharma DiveThe results support Takeda s long-held belief in zasocitinib s superiority and could help it gain a commercial advantage over Bristol s therapy.Immunology & InflammationRead full story pharminent June 11, 2026 (Last updated: June 11, 2026) BioPharma Dive The results support Takeda s long-held belief in zasocitinib s superiority and could help it gain a commercial advantage over Bristol s therapy. Immunology & Inflammation Read full story Post navigation Previous: Beren pockets $300m to take Niemann-Pick disease therapy to marketNext: SonoThera bags $125M series B to advance safer gene therapies Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
